Advanced search
Publication Cover
Toxicology Mechanisms and Methods Volume 25, 2015 - Issue 3
Submit an article Journal homepage
374
Views
24
CrossRef citations to date
0
Altmetric
Research Articles

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid

Jacqueline M. TarrantDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, Correspondence[email protected]
,
Preeti DhawanDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Jatinder SinghDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, ;Retrophin Inc., Cambridge, MA, USA,
,
Tanja S. ZabkaDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Emer ClarkeReachBio, Seattle, WA, USA,
,
Garry DosSantosReachBio, Seattle, WA, USA,
,
Peter S. DragovichDepartment of Discovery Chemistry and
,
Deepak SampathDepartment of Translational Oncology, Genentech Inc., South San Francisco, CA, USA, and
,
Tori LinDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Bobbi McCrayDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Nghi LaDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Trung NguyenDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Ariel KaussDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Donna DambachDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Dinah L. MisnerDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Dolores DiazDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
&
Hirdesh UppalDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, ;Medivation, San Francisco, CA, USA
 show all
Pages 201-211 | Received 13 Dec 2014, Accepted 27 Jan 2015, Published online: 20 Apr 2015

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Bianca M. Liederer, Jonathan Cheong, Kang-Jye Chou, Peter S. Dragovich, Hoa Le, Xiaorong Liang, Justin Ly, Sophie Mukadam, Jason Oeh, Deepak Sampath, Leslie Wang & Susan Wong. (2019) Preclinical assessment of the ADME, efficacy and drug-drug interaction potential of a novel NAMPT inhibitor. Xenobiotica 49:9, pages 1063-1077.
Read now
Keivan Sadrerafi, Emilia O Mason & Mark W Lee$suffix/text()$suffix/text(). (2018) Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors. Drug Design, Development and Therapy 12, pages 987-995.
Read now
Rabia Chaudhry, Adie Viljoen & Anthony S. Wierzbicki. (2018) Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Review of Clinical Pharmacology 11:6, pages 589-598.
Read now

Articles from other publishers (21)

Mahsa Yarhorhosseini, Shahrzad Javanshir, Ahmad Shahir Sadr, Milad Noori, Navid Dastyafteh, Maryam Esmkhani, Aida Iraji & Mohammad Mahdavi. (2023) Environmentally friendly catalyst- and solvent-free synthesis of 2-anilino nicotinic acids derivatives as potential lead COX inhibitors. BMC Chemistry 17:1.
Crossref
Fikriye Ozgencil & Gokcen Eren. (2023) Field-based 3D-QSAR studies on amide- and urea-containing NAMPT inhibitors. Chemometrics and Intelligent Laboratory Systems 242, pages 104984.
Crossref
Satenig Guler, Maria C. DiPoto, Alejandro Crespo, Richard Caldwell, Benjamin Doerfel, Nina Grossmann, Kevin Ho, Bayard Huck, Christopher CV Jones, Ruoxi Lan, Djordje Musil, Justin Potnick, Heike Schilke, Brian Sherer, Stephanie Simon, Christian Sirrenberg, Zhuo Zhang & Lesley Liu-Bujalski. (2023) Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression . ACS Medicinal Chemistry Letters 14:5, pages 566-576.
Crossref
QinChen Xu, Xiaoyan Liu, Ghazal Mohseni, Xiaodong Hao, Yidan Ren, Yiwei Xu, Huiru Gao, Qin Wang & Yunshan Wang. (2022) Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. Cancer Cell International 22:1.
Crossref
Kuojun Zhang, Kaizhen Wang, Xiangyu Zhang, Zhenlong Qian, Wenbo Zhang, Xiao Zheng, Jiaying Wang, Yin Jiang, Wanheng Zhang, Zhiyu Lu, Haiping Hao & Sheng Jiang. (2022) Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer. Journal of Medicinal Chemistry 65:11, pages 7746-7769.
Crossref
Sara Duarte-Pereira, Olga Fajarda, Sérgio Matos, José Luís Oliveira & Raquel Monteiro Silva. (2021) NAPRT Expression Regulation Mechanisms: Novel Functions Predicted by a Bioinformatics Approach. Genes 12:12, pages 2022.
Crossref
Giorgia Colombo, Edoardo Luigi Maria Gelardi, Federica Carolina Balestrero, Marianna Moro, Cristina Travelli & Armando A. Genazzani. (2021) Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer. Frontiers in Pharmacology 12.
Crossref
Moustafa S. Ghanem, Fiammetta Monacelli & Alessio Nencioni. (2021) Advances in NAD-Lowering Agents for Cancer Treatment. Nutrients 13:5, pages 1665.
Crossref
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, Jack D. Sadowsky, Emel Adaligil, Pragya Adhikari, Jinhua Chen, Nicholas Corr, Josefa dela Cruz-Chuh, Geoffrey Del Rosario, Aaron Fullerton, Steven J. Hartman, Fan Jiang, Susan Kaufman, Tracy Kleinheinz, Katherine R. Kozak, Liling Liu, Ying Lu, Melinda M. Mulvihill, Jeremy M. Murray, Aimee O’Donohue, Rebecca K. Rowntree, William S. Sawyer, Leanna R. Staben, John Wai, Jian Wang, BinQing Wei, Wentao Wei, Zijin Xu, Hui Yao, Shang-Fan Yu, Donglu Zhang, Hongyan Zhang, Shenhua Zhang, Yongxin Zhao, Hao Zhou & Xiaoyu Zhu. (2021) Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. Journal of Medicinal Chemistry 64:5, pages 2576-2607.
Crossref
Ubaldina Galli, Giorgia Colombo, Cristina Travelli, Gian Cesare Tron, Armando A. Genazzani & Ambra A. Grolla. (2020) Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy. Frontiers in Pharmacology 11.
Crossref
Daniel S. Palacios, Erik L. Meredith, Toshio Kawanami, Christopher M. Adams, Xin Chen, Veronique Darsigny, Mark Palermo, Daniel Baird, Elizabeth L. George, Chantale Guy, Jeffrey Hewett, Laryssa Tierney, Sachin Thigale, Louis Wang & Wilhelm A. Weihofen. (2019) Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT). ACS Medicinal Chemistry Letters 10:11, pages 1524-1529.
Crossref
Nathan R. Fons, Ranjini K. Sundaram, Gregory A. Breuer, Sen Peng, Ryan L. McLean, Aravind N. Kalathil, Mark S. Schmidt, Diana M. Carvalho, Alan Mackay, Chris Jones, Ángel M. Carcaboso, Javad Nazarian, Michael E. Berens, Charles Brenner & Ranjit S. Bindra. (2019) PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications 10:1.
Crossref
Daisuke Yamaguchi, Takamichi Imaizumi, Kaori Yagi, Yuichi Matsumoto, Takayuki Nakashima, Akiyo Hirose, Naomi Kashima, Yukino Nosaka, Tomoko Hamada, Katsuya Okawa, Yoichi Nishiya & Kazuo Kubo. (2019) Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening. Scientific Reports 9:1.
Crossref
Petr Svoboda, Edita Krizova, Sarka Sestakova, Kamila Vapenkova, Zdenek Knejzlik, Silvie Rimpelova, Diana Rayova, Nikol Volfova, Ivana Krizova, Michaela Rumlova, David Sykora, Rene Kizek, Martin Haluzik, Vaclav Zidek, Jarmila Zidkova & Vojtech Skop. (2019) Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle–dependent in mammalian cells, and its inhibition slows cell growth. Journal of Biological Chemistry 294:22, pages 8676-8689.
Crossref
Christopher S. Neumann, Kathleen C. Olivas, Martha E. Anderson, Julia H. Cochran, Steven Jin, Fu Li, Luke V. Loftus, David W. Meyer, Jason Neale, Jay C. Nix, Paul G. Pittman, Jessica K. Simmons, Michelle L. Ulrich, Andrew B. Waight, Abbie Wong, Margo C. Zaval, Weiping Zeng, Robert P. Lyon & Peter D. Senter. (2018) Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates. Molecular Cancer Therapeutics 17:12, pages 2633-2642.
Crossref
Genshi Zhao, Colin F. Green, Yu-Hua Hui, Lourdes Prieto, Robert Shepard, Sucai Dong, Tao Wang, Bo Tan, Xueqian Gong, Lisa Kays, Robert L. Johnson, Wenjuan Wu, Shobha Bhattachar, Miriam Del Prado, James R. Gillig, Maria-Carmen Fernandez, Ken D. Roth, Sean Buchanan, Ming-Shang Kuo, Sandaruwan Geeganage & Timothy P. Burkholder. (2017) Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration. Molecular Cancer Therapeutics 16:12, pages 2677-2688.
Crossref
Mark Zak, Po-wai Yuen, Xiongcai Liu, Snahel Patel, Deepak Sampath, Jason Oeh, Bianca M. Liederer, Weiru Wang, Thomas O’Brien, Yang Xiao, Nicholas Skelton, Rongbao Hua, Jasleen Sodhi, Yunli Wang, Lei Zhang, Guiling Zhao, Xiaozhang Zheng, Yen-Ching Ho, Kenneth W. Bair & Peter S. Dragovich. (2016) Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. Journal of Medicinal Chemistry 59:18, pages 8345-8368.
Crossref
Donna M. Dambach, Dinah Misner, Mathew Brock, Aaron Fullerton, William Proctor, Jonathan Maher, Dong Lee, Kevin Ford & Dolores Diaz. (2015) Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Chemical Research in Toxicology 29:4, pages 452-472.
Crossref
Dolores Diaz, Dylan P. Hartley & Raymond Kemper. 2016. Drug Discovery Toxicology. Drug Discovery Toxicology 530 539 .
Donna M. Dambach. 2016. Drug Discovery Toxicology. Drug Discovery Toxicology 13 26 .
Deepak Sampath, Tanja S. Zabka, Dinah L. Misner, Thomas O’Brien & Peter S. Dragovich. (2015) Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacology & Therapeutics 151, pages 16-31.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.